IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3019% above fair value
$0.19+0.01 (+7.37%)
Close on Nov 17, 2026Market cap $19.43MP/E –Yield –
IGC Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
IGC Pharma's operating income for the twelve months ending Jun 30, 2026 was -$11.08M. For fiscal 2025 it was -$7.45M. The highest annual figure on record is -$1.79M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | -$7.45M | – |
| FY2024 | Mar 31, 2024 | -$9.80M | – |
| FY2023 | Mar 31, 2023 | -$11.57M | – |
| FY2022 | Mar 31, 2022 | -$15.43M | – |
| FY2021 | Mar 31, 2021 | -$8.72M | – |
| FY2020 | Mar 31, 2020 | -$6.86M | – |
| FY2019 | Mar 31, 2019 | -$4.64M | – |
| FY2018 | Mar 31, 2018 | -$1.79M | – |
| FY2017 | Mar 31, 2017 | -$2.05M | – |
| FY2016 | Mar 31, 2016 | -$2.91M | – |
| FY2015 | Mar 31, 2015 | -$4.34M | – |
| FY2014 | Mar 31, 2014 | -$2.53M | – |
| FY2013 | Mar 31, 2013 | -$2.48M | – |
| FY2012 | Mar 31, 2012 | -$7.51M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$2.78M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$2.46M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$2.94M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$2.90M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$1.91M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$1.41M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$1.88M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$1.76M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$2.40M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$2.17M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$3.00M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$2.49M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$2.14M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$4.04M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$2.28M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$2.49M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$2.80M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$6.50M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$2.39M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$4.35M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$2.19M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$2.79M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$2.33M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$1.68M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$1.93M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$2.44M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$1.68M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$1.29M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$1.46M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$1.70M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$1.58M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$855.00K | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$511.00K | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$714.00K | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$473.00K | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$263.00K | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$396.27K | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$735.10K | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -$386.11K | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | -$549.63K | – |
See a number that looks wrong?